Utaa17
Relapsed/Refractory Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.N/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
497 Active assets in the Relapsed/Refractory Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Inno-206 University of Arkansas | Phase 3 | BBB |
Hyaluronidase fihj Massachusetts General Hospital | Phase 4 | BBB |
Busulphan M.D. Anderson Cancer Center | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →